GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » 3-Year Sharpe Ratio

GlycoNex (ROCO:4168) 3-Year Sharpe Ratio : -0.01 (As of Jul. 05, 2025)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-05), GlycoNex's 3-Year Sharpe Ratio is -0.01.


Competitive Comparison of GlycoNex's 3-Year Sharpe Ratio

For the Biotechnology subindustry, GlycoNex's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where GlycoNex's 3-Year Sharpe Ratio falls into.


;
;

GlycoNex 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


GlycoNex  (ROCO:4168) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


GlycoNex 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of GlycoNex's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex Business Description

Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The Company also provides antibody research services to its academic and industrial clients. The other services provided by the firm include functional evaluation and antibody engineering. The company has two segments which are antibody new drugs and exclusive investment. It earns the majority of its revenue from the antibody new drugs segment.

GlycoNex Headlines

No Headlines